Not enough data
Mandy Jackson's coverage focuses on the healthcare and pharmaceutical industry, particularly on drug development, FDA approvals, and biopharmaceutical companies. Additionally, she covers financial aspects related to these sectors.
Given her focus on press releases and private sector announcements, Mandy would likely be responsive to pitches that provide exclusive insights into new drug developments or financial activities within the healthcare and pharmaceutical industries. She may also be interested in expert commentary regarding regulatory changes impacting drug development or financial trends affecting biopharmaceutical companies.
While no specific geographic focus is mentioned for Mandy's coverage area, it’s important to note that her articles cover global developments in the healthcare and pharmaceutical sectors as well as finance-related topics relevant to these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mandy Jackson, May By
Public Company Edition: After three drug developer IPOs in Hong Kong and Korea in Q1, there have been three in Asia halfway through Q2, with HanchorBio listing in Taiwan soon. Also, RA Capital launched a SPAC, while Relay raised $275m and Immix grossed $150m in FOPOs.
By: Mandy Jackson, May By
Apogee signed a funding deal with Blackstone for up to $1.3bn as it reported competitive skin and itch benefits for its infrequently dosed IL-13 inhibitor zumilokibart in Part B of a Phase II study.
By: Mandy Jackson, May By
Replimune, which said it had no choice but to lay off employees after the FDA rejected its melanoma immunotherapy for a second time, will now submit the drug for its third review.
Deal Snapshot: In its second deal with an Asian company in two days, Lilly agreed to pay Haisco up to $3.05bn in upfront, near-term and milestone fees to discover up to five new drug candidates.
By: Mandy Jackson, Jun By
With Ipsen's Tazverik pulled from the market due to secondary hematologic malignancies, the US FDA said inhibition of the PRC2 complex was too risky. Pociredir targets the EED subunit, while Tazverik targets EZH2, but so far other drugs against those targets are not impacted.
By: Jun By, Mandy Jackson
Phase II data in bipolar I and II has bolstered private firm Autobahn's confidence in an upcoming 220-patient depression trial readout for thyroid hormone receptor agonist elunetirom.
By: Jun By, Mandy Jackson
Private Company Edition: Ending a recent lull in $100m-plus venture capital financings, NewLimit revealed its latest mega-round. Before that, Full-Life Technologies raised $150m in mid-May. Nearing mega-round territory, male contraceptive developer Contraline closed on $92.5m.
By: Jun By, Mandy Jackson
Deal Snapshot: Johnson & Johnson will pay $1bn in cash for privately held Firefly, gaining a degrader-antibody conjugate platform and preclinical programs, including RAS-targeting candidates.
By: Mandy Jackson, Jun By
City's siRNA drug targeting Factor XI is in Phase I and the company plans to take two more programs into the clinic soon while seeking partners for its CITY RNA platform.
By: Mandy Jackson, Jun By
The Portuguese drugmaker said BIA 28-6156 did not achieve the primary and key secondary endpoints in a Phase IIb trial of the drug in Parkinson's patients with a GBA1 gene variant.
